Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Epizyme Inc (NASDAQ:EPZM)

10.20
Delayed Data
As of Jan 20
 0.00 / 0.00%
Today’s Change
7.02
Today|||52-Week Range
13.46
-15.70%
Year-to-Date
Pluristem (PSTI) Intermittent Claudication Study Enrolled
Jan 13 / Zacks.com - Paid Partner Content
AbbVie's HCV Combo Favorable in Japanese Phase III Study
Jan 10 / Zacks.com - Paid Partner Content
TherapeuticsMD's Rejoice Study Data Published in Journal
Jan 12 / Zacks.com - Paid Partner Content
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
Jan 10 / Zacks.com - Paid Partner Content
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
Jan 12 / Zacks.com - Paid Partner Content
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
Jan 09 / Zacks.com - Paid Partner Content
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan 11 / Zacks.com - Paid Partner Content
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
Jan 09 / Zacks.com - Paid Partner Content
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
Jan 11 / Zacks.com - Paid Partner Content
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan 09 / Zacks.com - Paid Partner Content
Emergent Down on '17 View, Posts Preliminary '16 Results
Jan 10 / Zacks.com - Paid Partner Content